Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Icosavax reports Q2 EPS ($2.86), consensus ($2.23) » 16:15
09/13/21
09/13
16:15
09/13/21
16:15
ICVX

Icosavax

$37.97 /

-0.92 (-2.37%)

Reports Q2 revenue $1.9M,…

Reports Q2 revenue $1.9M, consensus $1.03M. "The second quarter and recent period has been a transformational time for Icosavax thanks to our initiation of two clinical trials, one in RSV and one in SARS-CoV-2, as well as our successful initial public offering and listing on the Nasdaq stock exchange. I would like to thank the entire Icosavax team for their hard work during this period, and I believe our company is now well-positioned to further advance the development of our VLP vaccine pipeline," said Adam Simpson, CEO of Icosavax. "Our novel VLP platform has shown promise to drive a robust, broad, and durable protective immune response to complex antigens. To this end, we are delighted to have recently initiated the Phase 1/1b trial of our RSV VLP vaccine candidate, IVX-121, in addition to the Phase 1/2 trial of our COVID-19 VLP vaccine candidate, IVX-411, and we look forward to providing future updates on these and our other programs."

ShowHide Related Items >><<
ICVX Icosavax
$37.97 /

-0.92 (-2.37%)

ICVX Icosavax
$37.97 /

-0.92 (-2.37%)

08/23/21 Evercore ISI
Icosavax initiated with an Outperform at Evercore ISI
08/23/21 Cowen
Icosavax initiated with Outperform on vaccine potential at Cowen
08/23/21 William Blair
Icosavax initiated with Outperform, $45.70 fair value at William Blair
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
  • 29
    Jul
ICVX Icosavax
$37.97 /

-0.92 (-2.37%)

Hot Stocks
Icosavax appoints Elizabeth Bekiroglu as general counsel » 08:05
09/10/21
09/10
08:05
09/10/21
08:05
ICVX

Icosavax

$39.46 /

-0.05 (-0.13%)

, SGEN

Seagen

$149.62 /

-3.08 (-2.02%)

Icosavax, Inc. (ICVX)…

Icosavax, Inc. (ICVX) announced the appointment of Elizabeth Bekiroglu to General Counsel. Prior to joining Icosavax, Ms. Bekiroglu was Associate General Counsel at Seagen (SGEN) where she helped lead and build the legal affairs group as Seagen transformed into a multi-product, multinational company.

ShowHide Related Items >><<
SGEN Seagen
$149.62 /

-3.08 (-2.02%)

ICVX Icosavax
$39.46 /

-0.05 (-0.13%)

ICVX Icosavax
$39.46 /

-0.05 (-0.13%)

08/23/21 Evercore ISI
Icosavax initiated with an Outperform at Evercore ISI
08/23/21 Cowen
Icosavax initiated with Outperform on vaccine potential at Cowen
08/23/21 William Blair
Icosavax initiated with Outperform, $45.70 fair value at William Blair
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
SGEN Seagen
$149.62 /

-3.08 (-2.02%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SGEN Seagen
$149.62 /

-3.08 (-2.02%)

  • 29
    Jul
ICVX Icosavax
$39.46 /

-0.05 (-0.13%)

Hot Stocks
Icosavax initiates Phase 1/1b trial of VLP vaccine candidate » 08:10
09/09/21
09/09
08:10
09/09/21
08:10
ICVX

Icosavax

$39.52 /

-0.03 (-0.08%)

Icosavax announced the…

Icosavax announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus stabilized pre-fusion F antigen, in healthy adults and older adults. Assuming favorable results from the IVX-121 Phase 1/1b clinical trial and favorable preclinical data from its human Metapneumovirus VLP candidate, Icosavax plans to thereafter initiate a Phase 1 clinical trial of its IVX-A12 bivalent RSV/hMPV vaccine candidate. The Phase 1/1b clinical trial of IVX-121 is a randomized, observer-blind, placebo-controlled multi-center study designed to evaluate the safety and immunogenicity of three dose levels of non-adjuvanted and aluminum-adjuvanted IVX-121 in healthy adults, including older adults. The trial will inform the dose of IVX-121 to be evaluated in combination with the Icosavax hMPV VLP candidate IVX-241 for the anticipated Phase 1 clinical trial of the RSV/hMPV bivalent vaccine candidate IVX-A12. The company plans to submit an investigational new drug application (IND) to the FDA in the first half of 2022 and, thereafter, initiate a Phase 1 clinical trial of IVX-A12.

ShowHide Related Items >><<
ICVX Icosavax
$39.52 /

-0.03 (-0.08%)

ICVX Icosavax
$39.52 /

-0.03 (-0.08%)

08/23/21 Evercore ISI
Icosavax initiated with an Outperform at Evercore ISI
08/23/21 Cowen
Icosavax initiated with Outperform on vaccine potential at Cowen
08/23/21 William Blair
Icosavax initiated with Outperform, $45.70 fair value at William Blair
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
  • 29
    Jul
ICVX Icosavax
$39.52 /

-0.03 (-0.08%)

Initiation
Icosavax initiated with an Outperform at Evercore ISI » 08:31
08/23/21
08/23
08:31
08/23/21
08:31
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

Evercore ISI analyst Josh…

Evercore ISI analyst Josh Schimmer initiated coverage of Icosavax with an Outperform rating and $50 price target. The company is leveraging a vaccine platform that addresses one of the key challenges in the field - scaling up virus-like Particles in a cost-effective manner, Schimmer tells investors in a research note. The analyst says that while the respiratory syncytial virus vaccine landscape is competitive, there are a few ways for Icosavax to differentiate.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

08/23/21 Cowen
Icosavax initiated with Outperform on vaccine potential at Cowen
08/23/21 William Blair
Icosavax initiated with Outperform, $45.70 fair value at William Blair
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Initiation
Icosavax initiated with Outperform on vaccine potential at Cowen » 08:18
08/23/21
08/23
08:18
08/23/21
08:18
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

Cowen analyst Phil Nadeau…

Cowen analyst Phil Nadeau initiated coverage of Icosavax with an Outperform rating and no price target. The company is developing virus-like particle vaccines against serious respiratory viruses and it also has a Covid vaccine in early clinical development, Nadeau tells investors in a research note. The analyst expects Icosavax to create shareholder value as its pipeline advances clinical development.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

08/23/21 William Blair
Icosavax initiated with Outperform, $45.70 fair value at William Blair
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
08/23/21 Cowen
Icosavax initiated with an Outperform at Cowen
  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Initiation
Icosavax initiated with Outperform, $45.70 fair value at William Blair » 07:38
08/23/21
08/23
07:38
08/23/21
07:38
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

William Blair analyst…

William Blair analyst Andy Hsieh initiated coverage of Icosavax with an Outperform rating. Using "conservative" parameters and assumptions, the analyst believes the fair value of Icosavax shares is roughly $1.8B, or $45.70 per share. The company stands to benefit from both the medical and investment communities' interests in identifying novel approaches that could disrupt the vaccine development paradigm beyond Covid, Hsieh tells investors in a research note. He believes the biotech sector is in a "prime position to disrupt the vaccine space, which historically has been dominated by big pharma." Icosavax's virus-like particle platform, in addition to its meticulous design using in silico techniques, differentiates it from other VLP modalities in that it is highly modular and amendable to incorporating a variety of antigens of interest, says Hsieh.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
08/23/21 Cowen
Icosavax initiated with an Outperform at Cowen
08/23/21 William Blair
Icosavax initiated with an Outperform at William Blair
  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Initiation
Icosavax initiated with a Buy at Jefferies » 07:36
08/23/21
08/23
07:36
08/23/21
07:36
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

Jefferies analyst Kelechi…

Jefferies analyst Kelechi Chikere initiated coverage of Icosavax with a Buy rating and $50 price target. Chikere tells investors in a research note that Phase I neutralizing antibodies data for Icosavax's RSV vaccine are expected in 1H2 and believes data for its CV-19 vaccine should help support the hypothesis that VLPs are better than other platforms at eliciting nAb. Positive data for other RSV vaccines coming as well will be a positive for Icosavax, the analyst contends.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

08/23/21 Jefferies
Icosavax initiated with a Buy at Jefferies
08/23/21 Cowen
Icosavax initiated with an Outperform at Cowen
08/23/21 William Blair
Icosavax initiated with an Outperform at William Blair
  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Initiation
Icosavax initiated with a Buy at Jefferies » 06:12
08/23/21
08/23
06:12
08/23/21
06:12
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

Jefferies analyst Kelechi…

Jefferies analyst Kelechi Chikere initiated coverage of Icosavax with a Buy rating.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

08/23/21 Cowen
Icosavax initiated with an Outperform at Cowen
08/23/21 William Blair
Icosavax initiated with an Outperform at William Blair
  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Initiation
Icosavax initiated with an Outperform at Cowen » 06:11
08/23/21
08/23
06:11
08/23/21
06:11
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

Cowen analyst Phil Nadeau…

Cowen analyst Phil Nadeau initiated coverage of Icosavax with an Outperform rating.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

08/23/21 William Blair
Icosavax initiated with an Outperform at William Blair
  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Initiation
Icosavax initiated with an Outperform at William Blair » 05:16
08/23/21
08/23
05:16
08/23/21
05:16
ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

William Blair analyst…

William Blair analyst Andy Hsieh initiated coverage of Icosavax with an Outperform rating.

ShowHide Related Items >><<
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

  • 29
    Jul
ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.